Cargando…
D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring
A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euth...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067842/ http://dx.doi.org/10.4103/2230-8210.342324 |
_version_ | 1784700097772126208 |
---|---|
author | Batra, Chandar M Kumar, Kiran Goyal, Monica |
author_facet | Batra, Chandar M Kumar, Kiran Goyal, Monica |
author_sort | Batra, Chandar M |
collection | PubMed |
description | A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euthyroid on treatment. The physical examination was unremarkable. Her liver, renal functions, thyroid, and adrenal functions were normal. At blood sugar of 23 mg/dl, her serum insulin was 24000uU/ml (normal<3uU/ml) and c-peptide was 16.2 ng/ml (normal 0-0.6ng/ml) which were very high. As the serum insulin levels were very high insulin autoimmune syndrome was suspected. Insulin autoantibodies were positive 87.2 units/ml (normal<12). Imaging with contrast-enhanced computerized tomography (CECT Abdomen), endoscopic ultrasonography, 68 gallium octreotide dotanoc whole-body PET -CT scan did not reveal any pancreatic or extra-pancreatic tumour. Autoimmune insulin syndrome (IAS) was diagnosed. She was started on high dose prednisolone, diazoxide and octreotide in addition to low carbohydrate meals. Hypoglycaemic episodes continued for 1 month despite this therapy. Remission was achieved only after 2 doses of Rituximab 1 gram infusion were given. Serum insulin levels were reduced to 230uU units from 24000uU/ml, and the patient's hypoglycaemic and hyperglycaemic episodes were normalized. We used continuous glucose monitoring using the Freestyle Libre glucose monitoring system, and the management of the patient was greatly facilitated with this. |
format | Online Article Text |
id | pubmed-9067842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-90678422022-05-05 D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring Batra, Chandar M Kumar, Kiran Goyal, Monica Indian J Endocrinol Metab Meet the Expert Cases…esicon 2021 A 67-year-old female presented with severe hypoglycaemia with a blood glucose of 34mg/dl 5 hours after having dinner. She did not have diabetes and had no access to oral hypoglycaemic agents, insulin, or any other drug known to cause hypoglycaemia. She was a known case of primary hypothyroidism euthyroid on treatment. The physical examination was unremarkable. Her liver, renal functions, thyroid, and adrenal functions were normal. At blood sugar of 23 mg/dl, her serum insulin was 24000uU/ml (normal<3uU/ml) and c-peptide was 16.2 ng/ml (normal 0-0.6ng/ml) which were very high. As the serum insulin levels were very high insulin autoimmune syndrome was suspected. Insulin autoantibodies were positive 87.2 units/ml (normal<12). Imaging with contrast-enhanced computerized tomography (CECT Abdomen), endoscopic ultrasonography, 68 gallium octreotide dotanoc whole-body PET -CT scan did not reveal any pancreatic or extra-pancreatic tumour. Autoimmune insulin syndrome (IAS) was diagnosed. She was started on high dose prednisolone, diazoxide and octreotide in addition to low carbohydrate meals. Hypoglycaemic episodes continued for 1 month despite this therapy. Remission was achieved only after 2 doses of Rituximab 1 gram infusion were given. Serum insulin levels were reduced to 230uU units from 24000uU/ml, and the patient's hypoglycaemic and hyperglycaemic episodes were normalized. We used continuous glucose monitoring using the Freestyle Libre glucose monitoring system, and the management of the patient was greatly facilitated with this. Wolters Kluwer - Medknow 2022-03 /pmc/articles/PMC9067842/ http://dx.doi.org/10.4103/2230-8210.342324 Text en Copyright: © 2022 Indian Journal of Endocrinology and Metabolism https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Meet the Expert Cases…esicon 2021 Batra, Chandar M Kumar, Kiran Goyal, Monica D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
title | D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
title_full | D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
title_fullStr | D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
title_full_unstemmed | D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
title_short | D1 MTE1 Case 1: Steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
title_sort | d1 mte1 case 1: steroid refractory insulin autoimmune syndrome treated with rituximab and continuous glucose monitoring |
topic | Meet the Expert Cases…esicon 2021 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067842/ http://dx.doi.org/10.4103/2230-8210.342324 |
work_keys_str_mv | AT batrachandarm d1mte1case1steroidrefractoryinsulinautoimmunesyndrometreatedwithrituximabandcontinuousglucosemonitoring AT kumarkiran d1mte1case1steroidrefractoryinsulinautoimmunesyndrometreatedwithrituximabandcontinuousglucosemonitoring AT goyalmonica d1mte1case1steroidrefractoryinsulinautoimmunesyndrometreatedwithrituximabandcontinuousglucosemonitoring |